48
Participants
Start Date
October 5, 2022
Primary Completion Date
March 12, 2025
Study Completion Date
May 22, 2025
Dolutegravir 0.5 mg/kg oral suspension
DTG 0.5 mg/kg liquid suspension administered orally
Dolutegravir 5 mg Dispersible Tablets
DTG 5 mg DT administered orally
Soweto, Johannesburg
Wits RHI Shandukani Research Centre CRS, Johannesburg
Umlazi, Durban
FAMCRU, Cape Town
Bronx-Lebanon Hospital Center NICHD CRS, The Bronx
Siriraj Hospital, Mahidol University NICHD CRS, Bangkok
Emory University School of Medicine NICHD CRS, Atlanta
Chiang Mai University HIV Treatment, Chiang Mai
Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Rai
Rush University, Cook County Hospital NICHD CRS, Chicago
Baylor College of Medicine/ Texas Children's Hospital NICHD CRS, Houston
University of Colorado Denver NICHD CRS, Aurora
USC - Maternal Child Adolescent/Adult Center, Los Angeles
David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles
St. Jude Children's Research Hospital, Memphis
Collaborators (1)
ViiV Healthcare
INDUSTRY
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Mental Health (NIMH)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH